Lilly Retatrutide Shows Greater A1C Reduction in Head-to-Head Trial
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% versus 1.8% with Ozempic. Lilly said retatrutide also produced more than double the weight loss of Ozempic’s highest approved dose.
Story updates
10:45:10 AM UTC
SquawkNews
ELI LILLY: RETATRUTIDE DELIVERED GREATER IMPROVEMENTS THAN OZEMPIC ACROSS CERTAIN CARDIOVASCULAR RIS
10:45:30 AM UTC
SquawkNews
ELI LILLY: AT 80 WEEKS, RETATRUTIDE MET PRIMARY & ALL KEY SECONDARY ENDPOINTS IN TRANSCEND-T2D-2, A
10:47:35 AM UTC
SquawkNews
Eli Lilly: retatrutide supera Ozempic nel calo di peso in studio di fase 3 Eli Lilly ha annuncia
10:49:13 AM UTC
SquawkNews
Topline data from the 80-week TRANSCEND-T2D-2 study showed retatrutide met the primary and all key s